NASHUA, N.H., Feb. 27, 2017 (GLOBE NEWSWIRE) -- iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of
advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today
announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2016 after the
market closes on Wednesday, March 8, 2017.
In addition, the Company will host a conference call beginning at 4:30 p.m. Eastern Time on Wednesday, March 8,
2017, to discuss the financial results and to provide a company update. The dial-in numbers are (855) 217-4501 for domestic callers
and (716) 220-9431 for international callers. The conference ID is 57732542. A live webcast of the conference call will be
available online at www.icadmed.com.
A replay of the webcast will remain on the Company’s website until the Company releases its first quarter 2017
financial results. In addition, a telephonic replay of the conference call will be available until March 15, 2017. The replay
dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. The replay conference ID is
57732542.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to
find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable
computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal
cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high
dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is
FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer
and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management
services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks,
uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially
different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such
factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and
strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or
difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and
manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased
competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our
existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the
Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”,
“demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only
as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in
this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our
public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Contact: For iCAD investor relations: The Ruth Group Zack Kubow 646-536-7020 iCAD@theruthgroup.com For iCAD media inquiries: Berry & Company Public Relations, LLC Lynn Granito, 212-253-8881 lgranito@berrypr.com
